Margetuximab

• CAT Number: I043769
• CAS Number: 1350624-75-7
• Purity: ≥95%

Margetuximab (MGAH22) is a chimeric anti-HER2 monoclonal antibody optimized Fc domain, with an EC50 value of 39.33 ng/mL. Margetuximab can be used for researching metastatic HER2-positive breast cancer[1].
Margetuximab (MGAH22) enhances the antibody-dependent cell-mediated cytotoxicity activity of effector cells expressing the CD16A-158F variant[1].
Margetuximab (2-4 mg/kg; IP 5 or 6 times at weekly) can firstly and significantly reduces the tumor size at day 30 – 37 in mice model[1].
Margetuximab (15-150 mg/kg; IV; 6 weekly) exhibits well tolerated in cynomolgus monkeys, decreases NK cells by an average of 51%, and induces IL-6 release[1].
Margetuximab (50 mg/kg; IV; single dosage) exhibits favorable safety profile[1].
Pharmacokinetic Parameters of Margetuximab in cynomolgus monkeys[1].

Male, IV (50 mg/kg)
Female, IV (50 mg/kg)

Cmax (mg/mL)
1.62 ± 0.10
1.70 ± 0.14

AUC0-¥ (mg·hour/mL)
294.1 ± 53.2
314.2 ± 31.3

T1/2β (days)
9.3 ± 1.8
9.7 ± 1.1

Clearance (mL/hour)
0.43 ± 0.07
0.40 ± 0.04

VSS (mL)
132 ± 2
127 ± 8

Reference

[1]. Nordstrom JL, et al. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties. Breast Cancer Res. 2011;13(6):R123. doi:10.1186/bcr3069